Beijing Fanzhi Medical Technology
Integrated solutions for rapid disease diagnostics.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | CNY100m | Series D | |
| Total Funding | 000k | ||
Related Content
Beijing Fanzhi Medical Technology Co., Ltd., also known as FireGen Biomedicals, is a global biopharmaceutical company established on June 3, 2016. The company was founded by a team of returning scientists, Chinese Academy of Sciences (CAS) scientists, and clinical experts, including Dr. Song Keqing, who serves as the founder and CEO. His background in precision medicine has guided the firm's focus. Fanzhi Medical has secured significant funding, including a Series D round of over 100 million CNY in September 2023 and a Series D+ round of a similar scale.
The company specializes in developing and providing integrated solutions for disease diagnostics. Its business model revolves around providing comprehensive "sample-in, result-out" solutions, including detection instruments, chips, diagnostic reagents, and internet-based remote diagnosis and treatment products. It has developed core competencies across four key technology areas: nucleic acids, chips, machinery, and software. Product lines include nucleic acid extraction kits, PCR amplification reagents, and diagnostic tools for conditions like respiratory infections and cardiovascular diseases. The firm's offerings are designed to make advanced, rapid diagnostics accessible to a wide range of clients, from primary care institutions and hospitals to communities and households.
Headquartered in Beijing, Fanzhi Medical operates large-scale GMP facilities, R&D centers, and medical laboratories in several Chinese provinces and has a presence in the United States. The company serves a global client base across more than 30 countries, which includes hospitals, pharmaceutical companies, research institutions, and genetic testing companies. It holds over 150 authorized patents and has received regulatory approvals from China's NMPA, the US FDA, and the European Union's CE for dozens of its products.
Keywords: disease diagnostics, biopharmaceutical, nucleic acid diagnostics, genetic testing, medical devices, PCR reagents, diagnostic instruments, molecular diagnostics, in-vitro diagnostics, precision medicine, point-of-care testing, diagnostic reagents, cardiovascular diseases diagnostics, respiratory infection testing, biotech, life sciences, medical technology, remote diagnosis, automated nucleic acid extraction
